当前位置：
X-MOL 学术
›
Chin. Chem. Lett.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Corrigendum to “An overview of polymeric nanomicelles in clinical trials and on the market” [Chinese Chemical Letters 32 (2021) 243-257]
Chinese Chemical Letters ( IF 9.4 ) Pub Date : 2024-11-16 , DOI: 10.1016/j.cclet.2024.110545 Xue Zheng, Jizhen Xie, Xing Zhang, Weiting Sun, Heyang Zhao, Yantuan Li, Cheng Wang
Chinese Chemical Letters ( IF 9.4 ) Pub Date : 2024-11-16 , DOI: 10.1016/j.cclet.2024.110545 Xue Zheng, Jizhen Xie, Xing Zhang, Weiting Sun, Heyang Zhao, Yantuan Li, Cheng Wang
The authors regret <According to ref. [90], the sentence on page 249 “A Phase I/II trial of NC-6004 plus gemcitabine for metastatic pancreatic cancer was conducted in Taiwan and Singapore (n = 22) [90].” should be revised to “A Phase I/II trial of NC-6004 plus gemcitabine for metastatic pancreatic cancer was conducted in the United States and Europe (n = 22) [90].”>.
更新日期：2024-11-16
京公网安备 11010802027423号